Omeros (NASDAQ:OMER) Given “Hold” Rating at Needham & Company LLC

Needham & Company LLC restated their hold rating on shares of Omeros (NASDAQ:OMER) in a research report sent to investors on Thursday,Benzinga reports.

Several other analysts also recently issued reports on OMER. Cantor Fitzgerald restated a “neutral” rating on shares of Omeros in a report on Thursday, November 14th. Rodman & Renshaw initiated coverage on shares of Omeros in a research report on Thursday, November 14th. They issued a “buy” rating and a $9.00 price target for the company. StockNews.com upgraded Omeros from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th. Finally, RODMAN&RENSHAW raised shares of Omeros to a “strong-buy” rating in a research report on Thursday, November 14th. Three investment analysts have rated the stock with a hold rating, one has issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $9.00.

Omeros Stock Performance

Shares of NASDAQ:OMER opened at $10.24 on Thursday. The company has a market capitalization of $593.41 million, a PE ratio of -4.43 and a beta of 1.97. The stock has a fifty day moving average of $6.96 and a 200-day moving average of $5.13. Omeros has a one year low of $2.61 and a one year high of $13.60.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of OMER. Bank of New York Mellon Corp lifted its position in Omeros by 16.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 218,580 shares of the biopharmaceutical company’s stock worth $887,000 after acquiring an additional 31,081 shares during the last quarter. AQR Capital Management LLC acquired a new stake in Omeros in the 2nd quarter valued at approximately $105,000. SPC Financial Inc. bought a new stake in shares of Omeros in the third quarter valued at approximately $77,000. Rhumbline Advisers grew its stake in shares of Omeros by 6.1% in the second quarter. Rhumbline Advisers now owns 111,778 shares of the biopharmaceutical company’s stock worth $454,000 after acquiring an additional 6,435 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its position in Omeros by 4.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 485,035 shares of the biopharmaceutical company’s stock worth $1,926,000 after acquiring an additional 18,454 shares during the period. 48.79% of the stock is currently owned by institutional investors and hedge funds.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.